New findings from two large-scale, international studies support the use of upfront treatment with abiraterone acetate (ZYTIGA) in men with metastatic prostate cancer.
The phase III international LATITUDE trial met its co-primary endpoints, demonstrating that adding abiraterone acetate plus prednisone (AA+P) to androgen deprivation therapy (ADT) significantly improved overall survival (OS) and significantly prolonged radiographic progression-free (rPFS) survival in men newly diagnosed with high-risk, metastatic castration-sensitive prostate cancer (mCRPC).
The second trial, STAMPEDE, found that abiraterone added to standard initial treatment reduced the risk of death by 37% over 3 years compared with standard of care alone in men with locally advanced or metastatic prostate cancer.
LATITUDE randomized 1,199 men 1:1 to ADT plus AA, 1,000 mg/day, and prednisone, 5 mg/day, or ADT plus placebos for both medications. Lead author Karim Fizazi, MD, PhD, from Gustave Roussy, Villejuif, France, presented findings from a first interim analysis that was planned to be done when about 50% of expected death events had occurred. It was conducted at a median follow-up of 30.4 months after 406 deaths.